GT200600031A - Formulacion anticuerpo anti a beta - Google Patents

Formulacion anticuerpo anti a beta

Info

Publication number
GT200600031A
GT200600031A GT200600031A GT200600031A GT200600031A GT 200600031 A GT200600031 A GT 200600031A GT 200600031 A GT200600031 A GT 200600031A GT 200600031 A GT200600031 A GT 200600031A GT 200600031 A GT200600031 A GT 200600031A
Authority
GT
Guatemala
Prior art keywords
agent
multimosis
polipeptides
abeta
manitol
Prior art date
Application number
GT200600031A
Other languages
English (en)
Inventor
Donna Luisi
Nicholas W Warne
Angela Kantor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600031A publication Critical patent/GT200600031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

LA PRESENTE INVENCIÓN PROVEE FROMULACIONES PARA MANTENER LA ESTABILIDAD DE LOS POLIPÉPTIDOS DE UNIÓN AL ABETA, POR EJEMPLO ANTICUERPOS ABETA. FORMULACIONES DE EJEMPLO INCLUYEN UN AGENTE DE TONICIDAD COMO EL MANITOL Y UN AGENTE ATENUADOR O AMINOÁCIDO COMO LA HISTIDINA. OTRAS FORMULACIONES DE EJEMPLO INLCUYEN UN ANTIOXIDANTE DE UNA CANTIDAD SUFICIENTE COMO PARA INHIBIR LA FORMACIÓN DE SUBPRODUCTOS, POR EJEMPLO, LA FORMACIÓN DE ACUMULADOS POLIPÉPTIDOS DE ALTO PESO MOLECULAR, FRAGMENTOS DE DEGRADACIÓN DE POLIPÉPTIDO DE BAJO PESO MOLECULAR, Y MEZCLAS DE LOS MISMOS. LAS FORMULACIONES DE LA INVENCIÓN OPCIONALMENTE COMPRENDEN UN AGENTE DE TONICIDAD, COMO EL MANITOL, Y UN AGENTE ATENUADOR O AMINO ÁCIDO COMO LA HISTIDINA. LAS FORMUACIONES SON ADECUADA PARA DIVERSAS RUTAS DE ADMINISTRACIÓN.
GT200600031A 2005-01-28 2006-01-26 Formulacion anticuerpo anti a beta GT200600031A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64863105P 2005-01-28 2005-01-28

Publications (1)

Publication Number Publication Date
GT200600031A true GT200600031A (es) 2006-08-29

Family

ID=36686080

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600031A GT200600031A (es) 2005-01-28 2006-01-26 Formulacion anticuerpo anti a beta

Country Status (30)

Country Link
US (2) US7635473B2 (es)
EP (2) EP1853310B1 (es)
JP (1) JP4977625B2 (es)
KR (1) KR101188060B1 (es)
CN (2) CN101262884B (es)
AR (1) AR052198A1 (es)
AU (1) AU2006211184B8 (es)
BR (1) BRPI0607039A2 (es)
CA (1) CA2593122C (es)
DK (1) DK1853310T3 (es)
DO (1) DOP2006000021A (es)
EA (2) EA015147B1 (es)
ES (1) ES2391407T3 (es)
GT (1) GT200600031A (es)
HK (3) HK1108132A1 (es)
IL (1) IL184599A (es)
JO (1) JO2740B1 (es)
MX (1) MX2007009050A (es)
MY (1) MY177052A (es)
NO (1) NO20073305L (es)
NZ (1) NZ556393A (es)
PE (1) PE20060879A1 (es)
PL (1) PL1853310T3 (es)
PT (1) PT1853310E (es)
SI (1) SI1853310T1 (es)
TW (1) TWI398263B (es)
UA (1) UA87549C2 (es)
UY (1) UY29351A1 (es)
WO (1) WO2006083689A2 (es)
ZA (1) ZA200705710B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP5362164B2 (ja) * 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN1745175A (zh) * 2003-02-01 2006-03-08 神经实验室有限公司 自动免疫产生针对可溶性A－β的抗体
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
ZA200703561B (en) * 2004-10-05 2009-09-30 Wyeth Corp Methods and compositions for improving recombinant protein production
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
SI3219328T1 (sl) * 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
ATE492561T1 (de) 2006-03-23 2011-01-15 Bioartic Neuroscience Ab Verbesserte protofibrilselektive antikörper und deren verwendung
WO2010044803A1 (en) * 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2011526240A (ja) * 2007-04-18 2011-10-06 ヤンセン アルツハイマー イミュノセラピー 脳アミロイド血管症の予防および治療
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
MX2009013886A (es) * 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
WO2009037190A2 (en) * 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
EP2205631B1 (en) * 2007-10-05 2016-11-23 Genentech, Inc. Methods and compositions for diagnosis and treatment of amyloidosis
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
KR101592156B1 (ko) 2008-05-23 2016-02-04 시와 코퍼레이션 재생을 촉진하는 방법, 조성물 및 장치
BRPI0915134A2 (pt) * 2008-06-12 2016-02-16 Affiris Ag composto, e, uso de um composto
EP2684570A1 (en) * 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX351706B (es) * 2010-09-17 2017-10-25 Baxalta Inc Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro.
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
BR112013024521A2 (pt) * 2011-03-25 2019-09-24 Genentech Inc métodos de purificação de proteínas
EA032625B1 (ru) * 2011-05-02 2019-06-28 Милленниум Фармасьютикалз, Инк. КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
JP2016536327A (ja) 2013-08-30 2016-11-24 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
JO3537B1 (ar) 2014-07-10 2020-07-05 Bioarctic Neuroscience Ab أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة
AU2015335828B2 (en) 2014-10-24 2018-08-23 Merck Sharp & Dohme Llc Co-agonists of the glucagon and GLP-1 receptors
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
MX2017014294A (es) * 2015-05-07 2018-08-09 Novimmune Sa Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EP4074730A1 (en) 2015-06-24 2022-10-19 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies with tailored affinity
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
EP3337829B1 (en) 2016-02-19 2020-01-08 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
CA3073066A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
KR20200044066A (ko) * 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
BR112020005335A2 (pt) * 2017-09-19 2020-09-24 Regeneron Pharmaceuticals, Inc. métodos para reduzir a formação de partículas e composições formadas pelos mesmos
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
EP4185612A1 (en) 2020-07-23 2023-05-31 Othair Prothena Limited Anti-abeta antibodies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2727112B2 (ja) * 1988-04-26 1998-03-11 コニカ株式会社 安定なペルオキシダーゼ組成物及び安定な抗体組成物
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0985033A4 (en) 1997-04-04 2005-07-13 Biosite Inc POLYVALENT AND POLYCLONAL LIBRARIES
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
JP2002511385A (ja) 1997-12-03 2002-04-16 ニューララブ リミテッド アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US7282570B2 (en) * 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6582945B1 (en) * 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
WO2001005355A2 (en) 1999-07-15 2001-01-25 Genetics Institute, Inc. Formulations for il-11
CZ306683B6 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
JP2003516929A (ja) * 2000-06-01 2003-05-20 ニユーララブ・リミテツド アミロイド形成性疾患の予防および治療
US7700751B2 (en) * 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US6916745B2 (en) * 2003-05-20 2005-07-12 Fairchild Semiconductor Corporation Structure and method for forming a trench MOSFET having self-aligned features
WO2002088307A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
EP1385545B1 (en) 2001-04-30 2009-01-07 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
EP1519740A4 (en) 2001-08-17 2005-11-09 Lilly Co Eli FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004055164A2 (en) * 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CN1745175A (zh) * 2003-02-01 2006-03-08 神经实验室有限公司 自动免疫产生针对可溶性A－β的抗体
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
PT2336147E (pt) 2003-12-17 2014-07-16 Janssen Alzheimer Immunotherap Conjugados transportadores de péptidos beta imunogénicos e seus processos de produção
SG182163A1 (en) 2003-12-17 2012-07-30 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
ES2282940T3 (es) * 2004-02-17 2007-10-16 Tyco Healthcare Group Lp Aparato para la aplicacion de grapas quirurgicas con mecanismo de bloqueo.
ZA200703561B (en) * 2004-10-05 2009-09-30 Wyeth Corp Methods and compositions for improving recombinant protein production
US20060160161A1 (en) * 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
WO2006066233A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
AR052051A1 (es) * 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
WO2006066118A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
JP2008528638A (ja) 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
WO2009017467A1 (en) * 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
JP2011526240A (ja) * 2007-04-18 2011-10-06 ヤンセン アルツハイマー イミュノセラピー 脳アミロイド血管症の予防および治療
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
PE20060879A1 (es) 2006-08-19
EP2392353A1 (en) 2011-12-07
KR20070108193A (ko) 2007-11-08
HK1196570A1 (zh) 2014-12-19
DOP2006000021A (es) 2006-08-15
NZ556393A (en) 2010-02-26
EP1853310A2 (en) 2007-11-14
CN101262884A (zh) 2008-09-10
NO20073305L (no) 2007-08-24
EA201100180A1 (ru) 2011-10-31
SI1853310T1 (sl) 2012-11-30
UY29351A1 (es) 2006-08-31
CN103768009A (zh) 2014-05-07
AU2006211184B8 (en) 2011-07-07
HK1118723A1 (en) 2009-02-20
MX2007009050A (es) 2008-04-04
EA021507B1 (ru) 2015-07-30
MY177052A (en) 2020-09-03
DK1853310T3 (da) 2012-10-22
TW200700080A (en) 2007-01-01
EA200701596A1 (ru) 2008-02-28
WO2006083689A3 (en) 2006-10-19
EA015147B1 (ru) 2011-06-30
PT1853310E (pt) 2012-10-22
CA2593122A1 (en) 2006-08-10
HK1108132A1 (en) 2008-05-02
CN103768009B (zh) 2016-02-24
KR101188060B1 (ko) 2012-10-24
ES2391407T3 (es) 2012-11-26
BRPI0607039A2 (pt) 2009-08-25
UA87549C2 (en) 2009-07-27
CA2593122C (en) 2012-03-06
IL184599A0 (en) 2007-10-31
AU2006211184A1 (en) 2006-08-10
CN101262884B (zh) 2012-10-31
US20060193850A1 (en) 2006-08-31
JP4977625B2 (ja) 2012-07-18
AR052198A1 (es) 2007-03-07
US8318164B2 (en) 2012-11-27
US7635473B2 (en) 2009-12-22
JO2740B1 (en) 2014-03-15
AU2006211184B2 (en) 2011-06-16
US20100166752A1 (en) 2010-07-01
TWI398263B (zh) 2013-06-11
ZA200705710B (en) 2008-10-29
EP1853310B1 (en) 2012-08-01
WO2006083689A2 (en) 2006-08-10
PL1853310T3 (pl) 2012-12-31
JP2008528612A (ja) 2008-07-31
IL184599A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
GT200600031A (es) Formulacion anticuerpo anti a beta
GT200600033A (es) Formulaciones liquidas estabilizadas de polipeptido
CL2020003102A1 (es) Molécula que tiene utilidad pesticida, y composiciones y procedimientos relacionados con la misma.
ECSP22046340A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
PE20200335A1 (es) Compuestos que inhiben la proteina mcl-1
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
PA8595001A1 (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
AR054428A1 (es) Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
HN2011000874A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
CU23856A3 (es) Composiciones que comprenden anticuerpo monoclonal chir-12.12
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
PA8623101A1 (es) Compuestos farmaceuticamente activos
UY29238A1 (es) Formulaciones de nepafenac para su administracion topica
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
ECSP13013050A (es) Formulación para anticuerpo anti- 4 7
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
UY30511A1 (es) Agonistas de ep2
CY1114838T1 (el) Φαρμακευτικες τοπικες συνθεσεις